Table 2.
Multivariate analyses of prognostic factors for disease-free survival and overall survival in the TARGET cohort.
| Prognostic factors | Multivariate analysis for DFS | Multivariate analysis for OS | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| LINC00173 expression | 1.946 (1.213–3.120) | 0.006 | 2.073 (1.211–3.547) | 0.008 |
| Age | 0.934 (0.550–1.584) | 0.799 | 1.371 (0.784–2.399) | 0.269 |
| WBC | 0.669 (0.398–1.126) | 0.130 | 1.023 (0.593–1.766) | 0.934 |
| MDR | 1.072 (0.649–1.770) | 0.787 | 1.280 (0.726–2.259) | 0.394 |
| ETV6/RUNX1 | 1.150 (0.527–2.508) | 0.726 | 0.446 (0.128–1.555) | 0.205 |
| TCF3/PBX1 | 4.985 (2.531–9.818) | <0.001 | 4.153 (2.112–8.167) | <0.001 |
| BCR/ABL1 | 1.372 (0.304–6.181) | 0.681 | 1.351 (0.379–4.816) | 0.643 |
| MLL-r | 1.557 (0.344–7.049) | 0.566 | 0.667 (0.085–5.263) | 0.701 |
| TCF3/HLF | 4.804 (0.607–38.016) | 0.137 | 6.944 (0.846–57.019) | 0.071 |
| iAMP21 | 1.464 (0.421–5.009) | 0.549 | 0.902 (0.204–3.996) | 0.892 |
| Hyperdiploidy | 0.613 (0.321–1.169) | 0.137 | 0.682 (0.327–1.418) | 0.305 |
Variables were composed of LINC00173 expression (high vs. low), age (<10 years vs. >10 years), WCB (<50 × 109/L vs. >50 × 109/L), MDR (<0.01% vs. >0.01% at day 29 of treatment), and subtypes (negative vs. molecular abnormality). WBC, white blood cells; MDR, minimal residual disease; HR, hazard ratio; CI, confidence interval; DFS, Disease-Free Survival; OS, Overall survival.